ECSP045065A - Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas - Google Patents

Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas

Info

Publication number
ECSP045065A
ECSP045065A EC2004005065A ECSP045065A ECSP045065A EC SP045065 A ECSP045065 A EC SP045065A EC 2004005065 A EC2004005065 A EC 2004005065A EC SP045065 A ECSP045065 A EC SP045065A EC SP045065 A ECSP045065 A EC SP045065A
Authority
EC
Ecuador
Prior art keywords
queratinocits
active substance
biologically active
wound treatment
treatment
Prior art date
Application number
EC2004005065A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045065A publication Critical patent/ECSP045065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención trata de queratinocitos novedosos que se puede cultivar in vitro y el uso ventajoso de esos para la fabricación de un producto, que puede ser usado para el tratamiento de heridas agudas y crónicas.
EC2004005065A 2001-10-17 2004-04-15 Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas ECSP045065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10151296A DE10151296A1 (de) 2001-10-17 2001-10-17 Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden

Publications (1)

Publication Number Publication Date
ECSP045065A true ECSP045065A (es) 2004-05-28

Family

ID=7702826

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005065A ECSP045065A (es) 2001-10-17 2004-04-15 Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas

Country Status (30)

Country Link
US (3) US7247478B2 (es)
EP (1) EP1440148B1 (es)
JP (1) JP4476625B2 (es)
KR (1) KR101019916B1 (es)
CN (1) CN100432220C (es)
AR (1) AR036827A1 (es)
AT (1) ATE474039T1 (es)
AU (1) AU2002349352B2 (es)
BR (1) BR0213282A (es)
CA (1) CA2461141C (es)
CO (1) CO5580844A2 (es)
DE (2) DE10151296A1 (es)
DK (1) DK1440148T3 (es)
EA (1) EA009073B1 (es)
EC (1) ECSP045065A (es)
ES (1) ES2345767T3 (es)
HR (1) HRP20040347B1 (es)
HU (1) HU228887B1 (es)
IL (2) IL161442A0 (es)
MX (1) MXPA04003487A (es)
MY (1) MY137828A (es)
NO (1) NO334974B1 (es)
NZ (1) NZ532899A (es)
PE (1) PE20030627A1 (es)
PL (1) PL367338A1 (es)
RS (1) RS30104A (es)
UA (1) UA81398C2 (es)
UY (1) UY27486A1 (es)
WO (1) WO2003033686A2 (es)
ZA (1) ZA200402306B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005012492A2 (en) * 2003-08-01 2005-02-10 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
WO2006010161A2 (en) * 2004-07-20 2006-01-26 The Regents Of The University Of California In vitro wound healing assay and device
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8080223B2 (en) * 2007-10-19 2011-12-20 Biointraface, Inc. Method of making a composite from metal oxide and polymer precursors
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2303293A1 (en) 2008-05-27 2011-04-06 Pluristem Ltd. Methods of treating inflammatory colon diseases
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP2711422B1 (en) * 2010-06-09 2014-10-01 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174769A1 (en) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN105219697A (zh) * 2014-07-04 2016-01-06 赫柏慧康生物科技无锡有限公司 一种人原代角质细胞分离制备的方法
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
US10668259B2 (en) 2015-10-21 2020-06-02 Materials Science Associates, LLC Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators
WO2017178472A1 (en) * 2016-04-12 2017-10-19 Unicyte Ev Ag Isolation of extracellular vesicles (evs) from biological fluid samples
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN109055303A (zh) * 2018-09-12 2018-12-21 山东麦德克斯生物科技有限公司 一种皮肤组织的构建方法
RU2731065C1 (ru) * 2019-12-24 2020-08-28 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) Состав криоконсерванта для длительного хранения первичных кератиноцитов

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016038A (en) * 1968-04-01 1977-04-05 Hayashibara Company Process for preparing maltoses from starches
US4016036A (en) * 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
IT1207525B (it) * 1987-06-23 1989-05-25 Ist Naz Ric Sul Cancro Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
IT1248934B (it) * 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
US6585969B1 (en) * 1991-11-20 2003-07-01 N. V. Innogenetics S.A. Non-viable keratinocyte cell composition or lysate for promoting wound healing
ATE307599T1 (de) * 1991-11-20 2005-11-15 Innogenetics Nv Keratinozyt-abstammende granulate zur verwendung als wundheilendes mittel
US5891617A (en) * 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693332C1 (en) * 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
AUPP244498A0 (en) * 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
DE19917532A1 (de) 1999-04-19 2000-10-26 Christian Toloczyki Trägergebundene kultivierte Stamm-bzw. Vorläuferzellen von Keratinozyten

Also Published As

Publication number Publication date
HUP0600341A2 (en) 2006-08-28
US7247478B2 (en) 2007-07-24
HU228887B1 (hu) 2013-06-28
US20070065419A1 (en) 2007-03-22
CA2461141A1 (en) 2003-04-24
JP4476625B2 (ja) 2010-06-09
IL161442A (en) 2012-02-29
HUP0600341A3 (en) 2011-03-28
EP1440148A2 (de) 2004-07-28
CO5580844A2 (es) 2005-11-30
RS30104A (sr) 2006-10-27
HRP20040347A2 (en) 2005-04-30
CA2461141C (en) 2011-12-06
US7754481B2 (en) 2010-07-13
UA81398C2 (en) 2008-01-10
MXPA04003487A (es) 2004-07-30
DE50214540D1 (de) 2010-08-26
US20080131967A1 (en) 2008-06-05
IL161442A0 (en) 2004-09-27
AU2002349352B2 (en) 2007-11-01
AR036827A1 (es) 2004-10-06
US7306943B2 (en) 2007-12-11
KR20040045856A (ko) 2004-06-02
EA200400482A1 (ru) 2004-12-30
WO2003033686A2 (de) 2003-04-24
PL367338A1 (en) 2005-02-21
ATE474039T1 (de) 2010-07-15
NZ532899A (en) 2006-04-28
DE10151296A1 (de) 2003-04-30
NO334974B1 (no) 2014-08-11
BR0213282A (pt) 2004-10-26
DK1440148T3 (da) 2010-09-27
WO2003033686A3 (de) 2004-02-12
EA009073B1 (ru) 2007-10-26
EP1440148B1 (de) 2010-07-14
JP2005505392A (ja) 2005-02-24
PE20030627A1 (es) 2003-07-16
ES2345767T3 (es) 2010-10-01
NO20041570L (no) 2004-04-16
KR101019916B1 (ko) 2011-03-08
ZA200402306B (en) 2006-05-31
HRP20040347B1 (en) 2012-07-31
MY137828A (en) 2009-03-31
CN100432220C (zh) 2008-11-12
US20030091542A1 (en) 2003-05-15
UY27486A1 (es) 2003-05-30
CN1571835A (zh) 2005-01-26

Similar Documents

Publication Publication Date Title
UY27486A1 (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
CR7786A (es) Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos
MX2008000243A (es) Material de curacion para heridas.
BR0209292A (pt) Uso compostos de complexos de metais como catalisadores de oxidação
TW200531702A (en) Pharmaceutical preparation comprising an antibody against the egf receptor
PE20030716A1 (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi) fenilamino] quinazolin-6-il} alil) acetamida y procedimiento de produccion
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
DE502005005048D1 (de) Wegwerfwindel, insbesondere zur inkontinentenversorgung
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
AU2002349352A1 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
SV2006002288A (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) ref. p-sv-79054/ug
DE60123100D1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
SV2009003403A (es) Extrudidos con enmascaramiento del sabor mejorado
ATE480244T1 (de) Neue, hyaluronsäure oder hyaluronsaure derivate und collagenase enthaltende pharmazeutische zusammensetzungen zur topischen behandlung von wunden, verbrennungen und geschwüren
MY149601A (en) Masking the taste of powders
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
UY26930A1 (es) Amidas de ácido fenilciclohexanocarboxílico sustituido y su uso
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
SE0102185D0 (sv) New subject-matter
ATE275551T1 (de) Halogenpyrimidine